Dipeptidyl peptidase 4 inhibitors in routine clinical practice: experiences from a Scottish teaching hospital


  • Amy L Brown Gartnavel General Hospital, Glasgow, G12 0YN, UK
  • Christopher R Sainsbury Gartnavel General Hospital, Glasgow, G12 0YN, UK
  • Carl Fenelon Glasgow Royal Infirmary, Glasgow, G4 0SF, UK
  • Alexander B Mullen Strathclyde Institute of Pharmacy & Biomedical Sciences, Glasgow, G4 0RE, UK
  • Gregory C Jones Gartnavel General Hospital, Glasgow, G12 0YN, UK




Aims: This study aimed to assess the effect of dipeptidyl peptidase 4 inhibitors (DPP4i) on glycaemia and weight control and review adherence to renal dosing guidance in routine clinical practice.

Methods: A retrospective review of type 2 diabetes patients prescribed a DPP4i was undertaken in a general hospital. Date, type and dose of DPP4i, HbA1c, weight and renal function were recorded at initiation of DPP4i therapy and at the first follow-up appointment at least 3 months later.

Results: Between March 2008 and June 2012, 335 patients were initiated on DPP4i therapy of whom 263 were eligible for study inclusion (baseline median HbA1c 73 mmol/mol (IQR 65-83), median weight 90.8kg (IQR 79.7-104), approximately 74.8% with eGFR >50ml/min/1.73m2). Sitagliptin 100mg daily was the most commonly prescribed DPP4i (90.5%). Median time between DPP4i initiation and follow-up was 189 days (IQR 140-239). At follow-up there was a reduction in HbA1c (median -8.5 mmol/mol; 95%CI -10, -6.5; p<0.005) and body weight (median -0.45kg; 95% CI -1.15, -0.25, p0.033). At initiation the dose of DPP4i was appropriate for 87.7% of patients.

Conclusions: DPP4i are effective in reducing HbA1c and body weight in routine specialist secondary care. Inappropriate prescribing in 70% of patients with eGFR <50ml/min/1.73m2 prompted a review of prescribing practice.


Karagiannis T, Paschos P, Paletas K, Matthews D, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012; 344:e1369. http://dx.doi.org/10.1136/bmj.e1369

Kim W, Egan J. The Role of Incretins in Glucose Homeostasis and Diabetes Treatment. Pharmacol Rev 2008;60:470-512. http://dx.doi.org/10.1124/pr.108.000604

Scottish Intercollegiate Guidelines Network. Guideline 116: Management of Diabetes- A National Clinical Guideline. March 2010. www.sign.ac.uk

National Institute for Health and Clinical Excellence. Clinical Guideline 87: Type 2 Diabetes -The Management of Type 2 Diabetes. May 2009. www.nice.org.uk

Fang V, Wazny LD, Raymond CB. Hypoglycaemics for the Treatment of Type 2 Diabetes in Patients With Chronic Kidney Disease: A Focus on New Agents. The CANNT Journal 2012;22:30-6.

Madsbad S, Krarup T, Deacon CF, et al. Glucagon-Like Peptide Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in the Treatment of Diabetes: A Review of Clinical Trials. Curr Opin Clin Nutr Metab Care 2008;11:491-9. http://dx.doi.org/10.1097/MCO.0b013e328302f414

Scheen AJ. DPP-4 Inhibitors in the Management of Type 2 Diabetes: A Critical Review of Head-to-Head Trials. Diabetes Metab 2012;38:89-101. http://dx.doi.org/10.1016/j.diabet.2011.11.001

Novartis Pharmaceuticals UK Ltd. Summary of Product Characteristics: Galvus® 50mg Tablets. Updated 21/8/12. Accessed via www.emc.medicines.org.uk

Merck, Sharpe and Dohme Ltd. Summary of Product Characteristics: Januvia® 25mg, 50mg, 100mg Tablets. Updated 17/09/12. Accessed via www.emc.medicines.org.uk

Bristol Meyers Squibb-AstraZeneca EEIG. Summary of Product Characteristics: Onglyza® 2,5mg and 5mg Tablets. Updated 11/1/12. Accessed via www.emc.medicines.org.uk

Boehring Ingelheim Ltd. Summary of Product Characteristics: Trajenta® 5mg Tablets. Updated 21/09/11. Accessed via www.emc.medicines.org.uk

Pani LN, Nathan DM, Grant RW. Clinical Predictors of Disease Progression and Medication Initiation in Untreated Patients with Type 2 Diabetes with A1c Less than 7%. Diabetes Care 2008;31:386-90. http://dx.doi.org/10.2337/dc07-1934

Bergman AJ, Cote J, Yi B, et al. Effect of Renal Insufficiency on the Pharmacokinetics of Sitagliptin – A Dipeptidyl Peptidase 4 Inhibitor. Diabetes Care 2007;30:1862-4. http://dx.doi.org/10.2337/dc06-2545

Boulton DW, Li L, Frevert EU, et al. Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin. Clin Pharmacokinet 2011; 50:253-65. http://dx.doi.org/10.2165/11584350-000000000-00000






Learning from practice

Most read articles by the same author(s)